Navalign LLC Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Navalign LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 8.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,227 shares of the biopharmaceutical company’s stock after selling 861 shares during the period. Navalign LLC’s holdings in Pfizer were worth $234,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Pfizer by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Pfizer by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock worth $3,190,131,000 after acquiring an additional 2,923,537 shares during the period. Norges Bank acquired a new stake in shares of Pfizer in the fourth quarter worth $2,328,986,000. Massachusetts Financial Services Co. MA increased its stake in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Pfizer by 7.7% in the fourth quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock worth $1,548,889,000 after acquiring an additional 4,167,222 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $25.23 on Tuesday. The company’s 50-day moving average price is $23.76 and its 200-day moving average price is $24.81. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a market cap of $143.44 billion, a P/E ratio of 18.28, a P/E/G ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the firm posted $0.82 earnings per share. The company’s revenue for the quarter was down 7.8% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.82%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analysts Set New Price Targets

PFE has been the topic of a number of research reports. TD Cowen cut their price objective on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Tuesday, April 22nd. The Goldman Sachs Group raised their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Wolfe Research raised their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.